Literature DB >> 31395243

Multimodality Imaging Markers of Adverse Myocardial Remodeling in Aortic Stenosis.

Thomas A Treibel1, Sveeta Badiani2, Guy Lloyd1, James C Moon3.   

Abstract

Aortic stenosis (AS) causes left ventricular remodeling (hypertrophy, remodeling, fibrosis) and other cardiac changes (left atrial dilatation, pulmonary artery and right ventricular changes). These changes, and whether they are reversible (reverse remodeling), are major determinants of timing and outcome from transcatheter or surgical aortic valve replacement. Cardiac changes in response to AS afterload can either be adaptive and reversible, or maladaptive and irreversible, when they may convey residual risk after intervention. Structural and hemodynamic assessment of AS therefore needs to evaluate more than the valve, and, in particular, the myocardial remodeling response. Imaging plays a key role in this. This review assesses how multimodality imaging evaluates AS myocardial hypertrophy and its components (cellular hypertrophy, fibrosis, microvascular changes, and additional features such as cardiac amyloid) both before and after intervention, and seeks to highlight how care and outcomes in AS could be improved.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic stenosis; aortic valve replacement; myocardial fibrosis; myocardial hypertrophy

Mesh:

Year:  2019        PMID: 31395243     DOI: 10.1016/j.jcmg.2019.02.034

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  7 in total

Review 1.  Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review.

Authors:  Brian R Lindman; Devraj Sukul; Marc R Dweck; Mahesh V Madhavan; Benoit J Arsenault; Megan Coylewright; W David Merryman; David E Newby; John Lewis; Frank E Harrell; Michael J Mack; Martin B Leon; Catherine M Otto; Philippe Pibarot
Journal:  J Am Coll Cardiol       Date:  2021-12-07       Impact factor: 24.094

Review 2.  Transcatheter Aortic Valve Replacement in the Coronavirus Disease 2019 (COVID-19) Era.

Authors:  Amgad Mentias; Hani Jneid
Journal:  J Am Heart Assoc       Date:  2020-05-26       Impact factor: 5.501

3.  Myocardial contractility recovery following acute pressure unloading after transcatheter aortic valve intervention (TAVI) in patients with severe aortic stenosis and different left ventricular geometry: a multilayer longitudinal strain echocardiographicanalysis.

Authors:  Sara Cimino; Sara Monosilio; Federico Luongo; Matteo Neccia; Lucia Ilaria Birtolo; Nicolò Salvi; Domenico Filomena; Massimo Mancone; Francesco Fedele; Luciano Agati; Viviana Maestrini
Journal:  Int J Cardiovasc Imaging       Date:  2020-11-30       Impact factor: 2.357

Review 4.  Multimodality Imaging for Discordant Low-Gradient Aortic Stenosis: Assessing the Valve and the Myocardium.

Authors:  Ezequiel Guzzetti; Mohamed-Salah Annabi; Philippe Pibarot; Marie-Annick Clavel
Journal:  Front Cardiovasc Med       Date:  2020-12-03

5.  Evaluation of Ventricular Remodeling and Prognosis in Patients with Aortic Stenosis Who Underwent Surgical or Percutaneous Transcatheter Aortic Valve Replacement.

Authors:  Rodrigo de Moura Joaquim; Tiago Ghislandi Nuernberg; Tammuz Fattah; Roberto Leo da Silva
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-02

6.  Left ventricular remodelling patterns in patients with moderate aortic stenosis.

Authors:  Jan Stassen; See Hooi Ewe; Kensuke Hirasawa; Steele C Butcher; Gurpreet K Singh; Mohammed R Amanullah; Kenny Y K Sin; Zee P Ding; Stephan M Pio; Nicholas W S Chew; Ching Hui Sia; William K F Kong; Kian Keong Poh; David J Cohen; Philippe Généreux; Martin B Leon; Nina Ajmone Marsan; Victoria Delgado; Jeroen J Bax
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-09-10       Impact factor: 9.130

7.  Spironolactone Inhibits Cardiomyocyte Hypertrophy by Regulating the Ca2+/Calcineurin/p-NFATc3 Pathway.

Authors:  Xin Wang; Wenting Zhang; Jingtao Na; Yanping Huo; Yacheng Wang; Ketong Liu
Journal:  J Healthc Eng       Date:  2021-12-16       Impact factor: 2.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.